Introduction: Metabolic syndrome is a well-recognized risk factor for cardiovascular diseases. It is associated with various disorders such as overweight and obesity, insulin resistance, type 2 diabetes mellitus and hypertension. Magnesium is an essential nutrient for maintaining vital physiological functions. Hypomagnesaemia may be implicated in the pathogenesis of various metabolic disorders such as overweight and obesity, insulin resistance, type 2 diabetes mellitus and hypertension. Hyperuricemia reflects defect in insulin action on the renal tubular reabsorption of uric acid in the renal system and may contribute to hypertension through its effect on the endothelium in the blood vessels. Objectives: To evaluate the role of serum Magnesium and Uric acid level in patients with metabolic syndrome. Methodology: We conducted an analytical case-control study on Metabolic Syndrome patients (N=90) and age matched healthy controls (N=90). Serum magnesium and Uric acid level were measured by colorimetric and Uricase-PAP method respectively. Results: We found that serum Magnesium levels were significantly decreased (0.8 ± 0.4 Mg/dl) in patients having metabolic syndrome as compared to healthy controls 2.0 ± 0.2 Mg/dl), whereas there were elevated levels of serum uric acid (10.5± 2.5 Mg/dl) in metabolic syndrome patients as compared to healthy controls (6.5 ±2.5 Mg/dl). Conclusions: Low serum magnesium levels have been associated with risk factors of metabolic syndrome, such as hyperglycemia, hypertension, hypertriglyceridemia and insulin resistance. Increased serum uric acid levels are commonly seen in patients with metabolic syndrome and are widely accepted as risk factors for hypertension and cardiovascular diseases.

Introduction: Metabolic syndrome is a well-recognized risk factor for cardiovascular diseases. It is associated with various disorders such as overweight and obesity, insulin resistance, type 2 diabetes mellitus and hypertension. Magnesium is an essential nutrient for maintaining vital physiological functions. Hypomagnesaemia may be implicated in the pathogenesis of various metabolic disorders such as overweight and obesity, insulin resistance, type 2 diabetes mellitus and hypertension. Hyperuricemia reflects defect in insulin action on the renal tubular reabsorption of uric acid in the renal system and may contribute to hypertension through its effect on the endothelium in the blood vessels. Objectives: To evaluate the role of serum Magnesium and Uric acid level in patients with metabolic syndrome. Methodology: We conducted an analytical case-control study on Metabolic Syndrome patients (N=90) and age matched healthy controls (N=90). Serum magnesium and Uric acid level were measured by colorimetric and Uricase-PAP method respectively. Results: We found that serum Magnesium levels were significantly decreased (0.8 ± 0.4 Mg/dl) in patients having metabolic syndrome as compared to healthy controls 2.0 ± 0.2 Mg/dl), whereas there were elevated levels of serum uric acid (10.5± 2.5 Mg/dl) in metabolic syndrome patients as compared to healthy controls (6.5 ±2.5 Mg/dl). Conclusions: Low serum magnesium levels have been associated with risk factors of metabolic syndrome, such as hyperglycemia, hypertension, hypertriglyceridemia and insulin resistance. Increased serum uric acid levels are commonly seen in patients with metabolic syndrome and are widely accepted as risk factors for hypertension and cardiovascular diseases.